Perspective Therapeutics' Updated Data On Its [212Pb]VMT-α-NET Program Accepted For Presentation At European Society Of Medical Oncology Congress 2026
Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
Perspective Therapeutics got approval to show their cancer-fighting medicine research at a big doctor conference next year. This means doctors will get to learn about their work, which is a normal step for companies testing new treatments.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.